Conference Dates

June 12 – 17, 2022


Middle East Respiratory Syndrome (MERS) is a respiratory disease caused by MERS coronavirus (MERS-CoV). In follow-up to a phase 1 trial, we performed a longitudinal analysis of immune responses following immunization with the Modified Vaccinia virus Ankara (MVA)-based vaccine MVA-MERS-S encoding MERS-CoV-spike protein. Three homologous intramuscular immunizations were administered on days 0 and 28 with a late booster vaccination at 12±4 months. Vaccination with MVA-MERS-S revealed a benign safety profile. No serious or severe adverse events were reported. Here, we analyzed innate and adaptive immune responses to the MVA-MERS-S in ten vaccinees. For this approach, blood samples were collected frequently for a period of about three years. Serum, plasma and PBMCs were analyzed at multiple time points using different techniques, which allowed an in-depth characterization of immune responses elicited by MVA-MERS-S.

Please click Download on the upper right corner to see the full abstract.